114 related articles for article (PubMed ID: 3544404)
21. Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro.
Kovach JS; Svingen PA
Invest New Drugs; 1984; 2(2):155-9. PubMed ID: 6469509
[TBL] [Abstract][Full Text] [Related]
22. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
23. Activity of 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt in M 5076/73A ovarian reticular cell sarcoma of the mouse.
Colombo T; Garattini S; Lassiani L; D'Incalci M
Cancer Treat Rep; 1982 Nov; 66(11):1945-8. PubMed ID: 6754075
[TBL] [Abstract][Full Text] [Related]
24. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M
Cancer Chemother Pharmacol; 1992; 30(6):459-64. PubMed ID: 1394802
[TBL] [Abstract][Full Text] [Related]
25. Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.
Zaharko DS; Covey JM; Hörpel G
Invest New Drugs; 1984; 2(2):149-54. PubMed ID: 6469508
[TBL] [Abstract][Full Text] [Related]
26. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B
Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679
[TBL] [Abstract][Full Text] [Related]
27. Experimental toxicology of ASTA Z 7557 (INN mafosfamide).
Pohl J; Hilgard P; Jahn W; Zechel HJ
Invest New Drugs; 1984; 2(2):201-6. PubMed ID: 6469515
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards.
Smith PC; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3459-63. PubMed ID: 3876834
[TBL] [Abstract][Full Text] [Related]
29. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
Sladek NE; Landkamer GJ
Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
[TBL] [Abstract][Full Text] [Related]
30. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
31. Effects of low dose pre-irradiation on hepatic damage and genetic material damage caused by cyclophosphamide.
Yu HS; Song AQ; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2014; 18(24):3889-97. PubMed ID: 25555880
[TBL] [Abstract][Full Text] [Related]
32. Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.
Zeller WJ; Berger MR; Matys R; Schuhmacher J
Invest New Drugs; 1984; 2(2):175-80. PubMed ID: 6469512
[TBL] [Abstract][Full Text] [Related]
33. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095
[TBL] [Abstract][Full Text] [Related]
34. Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host.
Greco G; Gabriele L; Rozera C; Venditti M; Belardelli F; Proietti E
Int J Cancer; 1995 Jul; 62(2):184-90. PubMed ID: 7622294
[TBL] [Abstract][Full Text] [Related]
35. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
Kawalec M; Skórski T; Kawiak J
Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
[TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells.
Schwartz PS; Waxman DJ
Mol Pharmacol; 2001 Dec; 60(6):1268-79. PubMed ID: 11723234
[TBL] [Abstract][Full Text] [Related]
37. Regional fibrosis after intraperitoneal administration of mafosfamide.
Roberts JD; Newman RA; Kimberly PJ; Hacker MP
Invest New Drugs; 1986; 4(1):61-5. PubMed ID: 2939038
[TBL] [Abstract][Full Text] [Related]
38. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
39. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.
Niemeyer U; Engel J; Scheffler G; Molge K; Sauerbier D; Weigert W
Invest New Drugs; 1984; 2(2):133-9. PubMed ID: 6469506
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
